- Home
- / SNBL
SNBL
Stock Price
¥1.2 K
2024-10-29
Market Capitalization
¥51.7 B
2024-10-29
Revenue
¥32.4 B
FY, 2025
SNBL Summary
Company Summary
- Overview
- SNBL (Shin Nippon Biomedical Laboratories, 株式会社 新日本科学) is a contract research company specializing in preclinical and clinical studies. It offers GLP (good laboratory practice), toxicity, pathology, pharmacokinetics, translational, and other research services. The company serves the pharmaceutical industry.
- Type
- Public
- Status
- Active
- Founded
- 1957
- HQ
- Tokyo, JP | view all locations
- Website
- https://www.snbl.co.jp/
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
Hideshi Tsusaki, President, Preclinical Services
Satoshi Matsumoto, Exective Director
Operating MetricsView all
Trademarks (US)
5
Nov, 2020
Patents (US)
26
Nov, 2020
Types of Services
4
Nov, 2020
LocationsView all
6 locations detected
Tokyo, Tokyo HQ
Japan
Akashicho 8-1 St. Luke Tower 28th floor
Everett, WA
United States
6605 Merrill Creek Pkwy
San Luis, AZ
United States
1962 Juan Sanchez Blvd
Kagoshima, Kagoshima
Japan
2438 Miyanourachō
Kainan, Tokyo
Japan
Minamiakasaka 16-1 (in Kainan Intelligent Park)
Osaka, Osaka
Japan
2-1-1 Fushimicho Sumitomo Mitsui Banking Corporation Koraibashi Building
SNBL Financials
Summary Financials
- Revenue (Q3, 2026)
- ¥21.2B
- Gross profit (Q3, 2026)
- ¥13.3B
- Net income (Q3, 2026)
- ¥2.2B
- Cash (Q3, 2026)
- ¥15.4B
- EBIT (Q3, 2026)
- ¥2.8B
- Enterprise value
- $77.9B